Spots Global Cancer Trial Database for Ribociclib (LEE011) Rollover Study for Continued Access
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Ribociclib (LEE011) Rollover Study for Continued Access
Official Title: An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments
Study ID: NCT02934568
Interventions
Study Description
Brief Summary: This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.
Detailed Description:
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Of Alabama At Birmingham, Birmingham, Alabama, United States
Dana Farber Cancer Institute Main Site, Boston, Massachusetts, United States
The Regents of the University of Michigan, Ann Arbor, Michigan, United States
Broome Oncology SC-2, Johnson City, New York, United States
St Jude Childrens Research Hospital, Memphis, Tennessee, United States
Novartis Investigative Site, Lyon, , France
Novartis Investigative Site, Villejuif, , France
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Tainan, , Taiwan
Novartis Investigative Site, Taipei, , Taiwan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
